FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W17659181> ?p ?o ?g. }

• W17659181 endingPage "47" @default.
• W17659181 startingPage "437" @default.
• W17659181 abstract "Pooled data from double-blind, placebo-controlled studies were utilized to compare the safety and efficacy of duloxetine in the treatment of major depressive disorder (MDD) in African-American and Caucasian patients.Efficacy and safety data were pooled from seven double-blind, placebo-controlled clinical trials of duloxetine. Patients (aged > or =18 years) meeting DSM-IV criteria for MDD received duloxetine (40-120 mg/day; African Americans, N=69; Caucasians, N=748) or placebo (African Americans, N=59; Caucasians, N=594) for up to nine weeks. Efficacy measures included the 17-item Hamilton Rating Scale for Depression (HAMD17) total score, the Clinical Global Impression of Severity (CGI-S) and Patient Global Impression of Improvement (PGI-I) scales, and Visual Analog Scales (VAS) for pain. Safety was assessed using discontinuation rates, spontaneously reported treatment-emergent adverse events, vital signs and laboratory analyses,Based upon mean changes in HAMD17, CGI-S and PGI-I scales, the magnitude of duloxetine's treatment effects did not differ significantly between African-American and Caucasian patients. Discontinuation rates due to adverse events among duloxetine-treated patients were 13.0% for African Americans and 17.0% for Caucasians. No adverse event led to discontinuation in more than one African-American patient. The most common treatment-emergent adverse events in both ethnic groups included nausea, headache, constipation, dizziness and insomnia. The rate of occurrence of these events did not differ significantly between African-American and Caucasian patients. Mean changes from baseline for pulse, blood pressure, weight and laboratory analytes were small and showed no significant differences between African-American and Caucasian patients.In this analysis of data from seven clinical trials, no convincing evidence was found to suggest that the overall safety and tolerability profile or the efficacy profile for duloxetine in this cohort of African-American patients differed from that observed in a comparator group of Caucasian patients. The results from these analyses provide supportive evidence for the efficacy and safety of duloxetine in the treatment of MDD in African-American patients." @default.
• W17659181 created "2016-06-24" @default.
• W17659181 creator A5013996499 @default.
• W17659181 creator A5042304299 @default.
• W17659181 creator A5070367435 @default.
• W17659181 creator A5078142817 @default.
• W17659181 creator A5091578640 @default.
• W17659181 date "2006-03-01" @default.
• W17659181 modified "2023-10-09" @default.
• W17659181 title "Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy." @default.
• W17659181 cites W1798630440 @default.
• W17659181 cites W1965262959 @default.
• W17659181 cites W1971393265 @default.
• W17659181 cites W1972523301 @default.
• W17659181 cites W1972859881 @default.
• W17659181 cites W1973239436 @default.
• W17659181 cites W1979917573 @default.
• W17659181 cites W1982721912 @default.
• W17659181 cites W1997077241 @default.
• W17659181 cites W2002958236 @default.
• W17659181 cites W2003363634 @default.
• W17659181 cites W2019268145 @default.
• W17659181 cites W2032895032 @default.
• W17659181 cites W2036948920 @default.
• W17659181 cites W2050513068 @default.
• W17659181 cites W2062639495 @default.
• W17659181 cites W2069090735 @default.
• W17659181 cites W2075102832 @default.
• W17659181 cites W2079375245 @default.
• W17659181 cites W2081990858 @default.
• W17659181 cites W2088723481 @default.
• W17659181 cites W2090401549 @default.
• W17659181 cites W2114010166 @default.
• W17659181 cites W2114613490 @default.
• W17659181 cites W2122306923 @default.
• W17659181 cites W2145158233 @default.
• W17659181 cites W2148438437 @default.
• W17659181 cites W2156197042 @default.
• W17659181 cites W2164718915 @default.
• W17659181 cites W2181560023 @default.
• W17659181 cites W2412810719 @default.
• W17659181 cites W72273208 @default.
• W17659181 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2576123" @default.
• W17659181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16573311" @default.
• W17659181 hasPublicationYear "2006" @default.
• W17659181 type Work @default.
• W17659181 sameAs 17659181 @default.
• W17659181 citedByCount "15" @default.
• W17659181 countsByYear W176591812012 @default.
• W17659181 countsByYear W176591812013 @default.
• W17659181 countsByYear W176591812015 @default.
• W17659181 countsByYear W176591812016 @default.
• W17659181 countsByYear W176591812020 @default.
• W17659181 countsByYear W176591812022 @default.
• W17659181 crossrefType "journal-article" @default.
• W17659181 hasAuthorship W17659181A5013996499 @default.
• W17659181 hasAuthorship W17659181A5042304299 @default.
• W17659181 hasAuthorship W17659181A5070367435 @default.
• W17659181 hasAuthorship W17659181A5078142817 @default.
• W17659181 hasAuthorship W17659181A5091578640 @default.
• W17659181 hasConcept C118552586 @default.
• W17659181 hasConcept C126322002 @default.
• W17659181 hasConcept C139719470 @default.
• W17659181 hasConcept C142724271 @default.
• W17659181 hasConcept C162324750 @default.
• W17659181 hasConcept C197934379 @default.
• W17659181 hasConcept C204787440 @default.
• W17659181 hasConcept C27081682 @default.
• W17659181 hasConcept C2776000289 @default.
• W17659181 hasConcept C2776867660 @default.
• W17659181 hasConcept C2778715236 @default.
• W17659181 hasConcept C2780051608 @default.
• W17659181 hasConcept C2780580376 @default.
• W17659181 hasConcept C2780733359 @default.
• W17659181 hasConcept C2780764818 @default.
• W17659181 hasConcept C535046627 @default.
• W17659181 hasConcept C71924100 @default.
• W17659181 hasConceptScore W17659181C118552586 @default.
• W17659181 hasConceptScore W17659181C126322002 @default.
• W17659181 hasConceptScore W17659181C139719470 @default.
• W17659181 hasConceptScore W17659181C142724271 @default.
• W17659181 hasConceptScore W17659181C162324750 @default.
• W17659181 hasConceptScore W17659181C197934379 @default.
• W17659181 hasConceptScore W17659181C204787440 @default.
• W17659181 hasConceptScore W17659181C27081682 @default.
• W17659181 hasConceptScore W17659181C2776000289 @default.
• W17659181 hasConceptScore W17659181C2776867660 @default.
• W17659181 hasConceptScore W17659181C2778715236 @default.
• W17659181 hasConceptScore W17659181C2780051608 @default.
• W17659181 hasConceptScore W17659181C2780580376 @default.
• W17659181 hasConceptScore W17659181C2780733359 @default.
• W17659181 hasConceptScore W17659181C2780764818 @default.
• W17659181 hasConceptScore W17659181C535046627 @default.
• W17659181 hasConceptScore W17659181C71924100 @default.
• W17659181 hasIssue "3" @default.
• W17659181 hasLocation W176591811 @default.
• W17659181 hasOpenAccess W17659181 @default.
• W17659181 hasPrimaryLocation W176591811 @default.

• next